EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset

Yan Li, Daniel Yen, Rachel D Hendrix, Brian A Gordon iD, Sibonginkhosi Dlamini, Nicolas R Barthélemy, Andrew J Aschenbrenner iD, Rachel L Henson, Elizabeth M Herries, Katherine Volluz, Kristopher Kirmess, Stephanie Eastwood und 10 weitere

Annals of Neurology · 2024

DOI: 10.1002/ana.26891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2024. Verfasst von Yan Li und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH HHS, BrightFocus Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A clock relating amyloid positron emission tomography (PET) to time was used to estimate the timing of biomarker changes in sporadic Alzheimer disease (AD).

Methods

Research participants were included who underwent cerebrospinal fluid (CSF) collection within 2 years of amyloid PET. The ages at amyloid onset and AD symptom onset were estimated for each individual. The timing of change for plasma, CSF, imaging, and cognitive measures was calculated by comparing restricted cubic splines of cross‐sectional data from the amyloid PET positive and negative groups.

Results

The amyloid PET positive sub‐cohort (n = 118) had an average age of 70.4 ± 7.4 years (mean ± standard deviation) and 16% were cognitively impaired. The amyloid PET negative sub‐cohort (n = 277) included individuals with low levels of amyloid plaque burden at all scans who were cognitively unimpaired at the time of the scans. Biomarker changes were detected 15–19 years before estimated symptom onset for CSF Aβ42/Aβ40, plasma Aβ42/Aβ40, CSF pT217/T217, and amyloid PET; 12–14 years before estimated symptom onset for plasma pT217/T217, CSF neurogranin, CSF SNAP‐25, CSF sTREM2, plasma GFAP, and plasma NfL; and 7–9 years before estimated symptom onset for CSF pT205/T205, CSF YKL‐40, hippocampal volumes, and cognitive measures.

Interpretation

The use of an amyloid clock enabled visualization and analysis of biomarker changes as a function of estimated years from symptom onset in sporadic AD. This study demonstrates that estimated years from symptom onset based on an amyloid clock can be used as a continuous staging measure for sporadic AD and aligns with findings in autosomal dominant AD. ANN NEUROL 2024;95:951–965

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersAmyloid beta-PeptidesPositron-Emission TomographyHumansFemaleMaleAgedMiddle AgedPeptide FragmentsAged, 80 and overCross-Sectional StudiesTime FactorsAge of OnsetCohort StudiesDisease ProgressionChitinase-3-Like Protein 1Cognitive DysfunctionPlaque, Amyloid

Substanzen

BiomarkersAmyloid beta-PeptidesPeptide Fragmentsamyloid beta-protein (1-42)Chitinase-3-Like Protein 1amyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
  • C2N Diagnostics, St. Louis, MO, USA.
  • Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
  • Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.

ORCID-Profile: Brian A Gordon, Andrew J Aschenbrenner, Eric McDade, Suzanne E Schindler

Förderung

  • NIA NIH HHS
  • NIH HHS
  • BrightFocus Foundation
  • Alzheimer's Drug Discovery Foundation
  • National Institute on Aging
  • National Institutes of Health

Zitieren

APA

Li, Y., Yen, D., Hendrix, R. D., Gordon, B. A., Dlamini, S., Barthélemy, N. R., Aschenbrenner, A. J., Henson, R. L., Herries, E. M., Volluz, K., Kirmess, K., Eastwood, S., Meyer, M., Heller, M., Jarrett, L., McDade, E., Holtzman, D. M., Benzinger, T. L. S., Morris, J. C., …, & Schindler, S. E. (2024). Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. Annals of Neurology. https://doi.org/10.1002/ana.26891

Vancouver

Li Y, Yen D, Hendrix RD, Gordon BA, Dlamini S, Barthélemy NR, et al. Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. Annals of Neurology. 2024. doi:10.1002/ana.26891

BibTeX
@article{Li2024,
  author = {Li, Yan and Yen, Daniel and Hendrix, Rachel D and Gordon, Brian A and Dlamini, Sibonginkhosi and Barthélemy, Nicolas R and Aschenbrenner, Andrew J and Henson, Rachel L and Herries, Elizabeth M and Volluz, Katherine and Kirmess, Kristopher and Eastwood, Stephanie and Meyer, Matthew and Heller, Maren and Jarrett, Lea and McDade, Eric and Holtzman, David M and Benzinger, Tammie L S and Morris, John C and Bateman, Randall J and Xiong, Chengjie and Schindler, Suzanne E},
  title = {Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset},
  journal = {Annals of Neurology},
  year = {2024},
  doi = {10.1002/ana.26891}
}
Kostenlos starten →